ARQT

29.02

1.53% -0.45

Handel nachbörslich: 29.03 0.01 +0.03%

Arcutis Biotherapeutics Inc (ARQT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ARQT? Forum Prognose

Schlusskurs vom Vortag:

$29.47

Offen:

$29.35

24-Stunden-Volumen:

1.73M

Relative Volume:

0.76

Marktkapitalisierung:

$3.55B

Einnahmen:

$59.61M

Nettoeinkommen (Verlust:

$-262.14M

KGV:

-7.4031

EPS:

-3.92

Netto-Cashflow:

$-247.49M

1W Leistung:

-6.99%

1M Leistung:

+23.75%

6M Leistung:

+114.96%

1J Leistung:

+136.90%

1-Tages-Spanne:

$28.30

$29.50

1-Wochen-Bereich:

$28.30

$31.77

52-Wochen-Spanne:

$11.13

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Firmenname

Arcutis Biotherapeutics Inc

Sektor

Healthcare (1123)

Branche

Biotechnology (627)

Telefon

805-418-5006

Adresse

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Mitarbeiter

342

Twitter

@ArcutisBio

Nächster Verdiensttermin

2024-12-06

Neueste SEC-Einreichungen

ARQT's Discussions on Twitter

Vergleichen Sie ARQT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARQT Arcutis Biotherapeutics Inc	29.02	3.61B	59.61M	-262.14M	-247.49M	-3.92
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-25	Eingeleitet	Goldman	Neutral
2024-12-30	Eingeleitet	H.C. Wainwright	Buy
2024-08-28	Eingeleitet	Jefferies	Buy
2024-01-03	Hochstufung	Mizuho	Neutral → Buy
2023-10-26	Herabstufung	Mizuho	Buy → Neutral
2023-10-13	Herabstufung	Goldman	Buy → Neutral
2022-09-07	Eingeleitet	Needham	Buy
2022-03-17	Eingeleitet	Goldman	Buy
2021-06-30	Eingeleitet	Mizuho	Buy
2021-05-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-11-09	Hochstufung	Goldman	Neutral → Buy
2020-10-08	Eingeleitet	Truist	Buy
2020-02-25	Eingeleitet	Cantor Fitzgerald	Overweight
2020-02-25	Eingeleitet	Cowen	Outperform
2020-02-25	Eingeleitet	Goldman	Neutral
2020-02-25	Eingeleitet	Guggenheim	Buy

Alle ansehen

Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten

Dec 11, 2025

Tori Spelling Teams Up with Arcutis to Share Her Family’s Eczema Journey - WKEF

Dec 11, 2025

Looking Into Arcutis Biotherapeutics Inc's Recent Short Interest - Benzinga

Dec 11, 2025

Dec 10, 2025

What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? - sharewise.com

Dec 10, 2025

Stempoint Capital LP Sells 334,401 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Dec 10, 2025

Dec 09, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected - simplywall.st

Dec 09, 2025

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - BioSpace

Dec 09, 2025

Dec 08, 2025

Arcutis Biotherapeutics Appoints Amit Munshi as New Director - TipRanks

Dec 08, 2025

Arcutis Biotherapeutics Announces Board Changes - TradingView

Dec 08, 2025

Amit Munshi joins Arcutis board as founder Chaudhuri retires By Investing.com - Investing.com India

Dec 08, 2025

Arcutis strengthens board of directors with new appointment of Amit Munshi - marketscreener.com

Dec 08, 2025

Arcutis Strengthens Board of Directors with New Appointment - GlobeNewswire

Dec 08, 2025

Arcutis Biotherapeutics | 12/8/25 - Channel 13 Las Vegas News KTNV

Dec 08, 2025

Arcutis Biotherapeutics: The Earnings Inflection Has Arrived (ARQT) - Seeking Alpha

Dec 08, 2025

Dec 07, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 07, 2025

Dec 06, 2025

Arcutis Biotherapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Dec 06, 2025

XTX Topco Ltd Reduces Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Dec 06, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat

Dec 06, 2025

Dec 05, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 1-Year HighStill a Buy? - MarketBeat

Dec 05, 2025

What risks investors should watch in Arcutis Biotherapeutics Inc. stockRate Cut & Reliable Breakout Forecasts - Newser

Dec 05, 2025

Dec 04, 2025

Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat

Dec 04, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 1,657 Shares - MarketBeat

Dec 04, 2025

Arcutis Biotherapeutics stock hits 52-week high at 31.29 USD - Investing.com

Dec 04, 2025

Arcutis Biotherapeutics stock hits 52-week high at 31.29 USD By Investing.com - Investing.com Canada

Dec 04, 2025

Dec 03, 2025

Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Bioth - GuruFocus

Dec 03, 2025

Assessing Arcutis Biotherapeutics (ARQT) Valuation After Its Strong 1-Year Share Price Surge - Yahoo Finance

Dec 03, 2025

Arcutis Biotherapeutics Insider Sold Shares Worth $302,133, According to a Recent SEC Filing - marketscreener.com

Dec 03, 2025

AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension - Finviz

Dec 03, 2025

Dec 02, 2025

Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock? - sharewise.com

Dec 02, 2025

Arcutis Biotherapeutics: Behind The Big Rally (NASDAQ:ARQT) - Seeking Alpha

Dec 02, 2025

(ARQT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com

Dec 02, 2025

American Century Companies Inc. Purchases 71,815 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Dec 02, 2025

Nov 29, 2025